Testing an NMDA enhancer alone for schizophrenia in adults
Tests an NMDA enhancer drug alone in adults with schizophrenia, compared with placebo.
Plain-language title generated from the registry record
Registry title: Monotherapy of an NMDA Enhancer for Schizophrenia
Key facts
- Where
- Taichung, TaiwanSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT04745143, who can take part
Where in Taiwan
- Department of Psychiatry, China Medical University HospitalTaichung, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- China Medical University Hospital
- Trial code
- NCT04745143
- Record updated
- 24 March 2026
- Original description
Previous studies found that some NMDA-enhancing agent was able to augment antioxidant activity and its adjunctive therapy was better than placebo in reducing clinical symptoms and cognitive deficits and revealed favorable safety in patients with chronic schizophrenia. Of note, a substantial portion of schizophrenia patients refuse or cannot tolerate antipsychotics due to poor response or severe side effects. Therefore, this study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) as a monotherapy for the treatment of schizophrenia.Read full original descriptionShow less
Monotherapy of an NMDA Enhancer for Schizophrenia
Previous studies found that some NMDA-enhancing agent was able to augment antioxidant activity and its adjunctive therapy was better than placebo in reducing clinical symptoms and cognitive deficits and revealed favorable safety in patients with chronic schizophrenia. Of note, a substantial portion of schizophrenia patients refuse or cannot tolerate antipsychotics due to poor response or severe side effects. Therefore, this study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) as a monotherapy for the treatment of schizophrenia.
Inclusion: Have a DSM-5 (American Psychiatric Association) diagnosis of schizophrenia; Refuse or are unable to tolerate antipsychotics due to poor response or adverse effects; PANSS total score ≥ 60; Free of antipsychotic drugs for at least 1 week; Agree to participate in the study and provide informed consent.
Exclusion: Current substance abuse or history of substance dependence in the past 3 months; History of epilepsy, head trauma, stroke or other serious medical or neurological illness which may interfere with the study; Clinically significant laboratory screening tests; Use of depot antipsychotic in the past 3 months; Pregnancy or lactation; Inability to follow protocol.